Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewCMPDA is a positive allosteric modulator of GluA2 receptors (EC50 values are 45.4 and 63.4 nM at GluA2i and GluA2o respectively, in a calcium influx screening assay). Binds at the modulator binding pocket located at the interdimer interface and the clamshell hinges.
分子量 | 376.53 |
公式 | C16H28N2O4S2 |
储存 | Store at +4°C |
纯度 | ≥98% (HPLC) |
CAS Number | 380607-77-2 |
PubChem ID | 9969799 |
InChI Key | FHLGMMYEKXPVSC-UHFFFAOYSA-N |
Smiles | O=S(NCCC1=CC=C(CCNS(=O)(C(C)C)=O)C=C1)(C(C)C)=O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Timm et al (2011) Structural and functional analysis of two new positive allosteric modulators of GluA2 desensitization and deactivation. Mol.Pharmacol. 80 267 PMID: 21543522
关键词: CMPDA, CMPDA supplier, Positive, allosteric, modulators, GluR2, GluA2, AMPA, receptors, GluR2i, GluA2i, GluR2o, GluA2o, PAM, Receptors, 4373, Tocris Bioscience
目前没有该产品的评论。 Be the first to review CMPDA and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.